tremelimumab astrazeneca
astrazeneca ab - tremelimumab - carcinom, ikke-småcellet lunge - antineoplastiske midler - tremelimumab astrazeneca in combination with durvalumab and platinum-based chemotherapy is indicated for the first-line treatment of adults with metastatic non-small cell lung cancer (nsclc) with no sensitising egfr mutations or alk positive mutations.
everolimus "stada" 10 mg tabletter
stada arzneimittel ag - everolimus - tabletter - 10 mg
everolimus "stada" 2,5 mg tabletter
stada arzneimittel ag - everolimus - tabletter - 2,5 mg
everolimus "stada" 5 mg tabletter
stada arzneimittel ag - everolimus - tabletter - 5 mg
everolimus "sandoz" 2,5 mg tabletter
sandoz a/s - everolimus - tabletter - 2,5 mg
everolimus "mylan" 2,5 mg tabletter
orifarm a/s - everolimus - tabletter - 2,5 mg